COPENHAGEN, March 7 (Reuters) - Novo Nordisk
will increase its capital expenditure to build its fill-finish
capacity if the company does not close the planned Catalent ( CTLT )
acquisition, the Danish drugmaker's Chief Financial
Officer Karsten Munk Knudsen said on Thursday.
Novo would also do more deals with contract drugmakers if
the company does not complete the Catalent ( CTLT ) purchase, Knudsen
told analysts at Novo's capital markets day.